Introduction
Space limitations prevent a comprehensive review of this area, and topics have been selected to provide examples of important advances in certain speci®c areas of this ®eld. Mitochondria occupy a pivotal role in metabolic pathways that are critical for both cell survival (oxidative phosphorylation) and cell death (apoptosis). Abnormalities of oxidative phosphorylation, in particular, in respiratory chain function, have been recognized as important causes of human disease. Respiratory chain de®ciency may be primary or secondary (Table 1) . Primary disorders include those that are caused by mutations in mitochondrial DNA (mtDNA) and in nuclear genes that encode subunits of the respiratory chain complexes and adenosine triphosphate synthase (complex V). Secondary disorders include those that are caused by, or associated with, mutations in nuclear genes that encode nonrespiratory chain mitochondrial proteins, or dysfunction or de®ciency in other proteins that may in turn affect respiratory chain activity. Several recent reviews [1±3] have covered the subjects of mtDNA, respiratory chain and oxidative phosphorylation system structure and function, and these topics are not covered in the present review.
It was generally believed that mtDNA is inherited in a strictly maternal fashion. However, this assumption was based on studies that lacked the sensitivity to detect very small concentrations of (paternal) mtDNA. Furthermore, there is evidence for paternal leakage of mtDNA in mice [4] , although this may subsequently be 527 [7] . The ratio of mtDNA molecule number in sperm to that in ova is estimated at 1 : 70±1000 [8] ; thus, any paternal mtDNA would be present in small proportion relative to maternal mtDNA. DNA ampli®cation techniques failed to demonstrate paternal mtDNA in offspring with a sensitivity level up to 0.01%. Thus, the process of direct injection of sperm mtDNA into the oocyte did not result in detectable levels of replicated paternal mtDNA in offspring, implying that no mtDNA-associated disorder could be transmitted by this process.
Although numerous disorders are caused by, or associated with de®ciency in respiratory chain function, correlations between the severity of enzyme defect, oxidative phosphorylation [adenosine triphosphate (ATP) synthesis] capacity and cell dysfunction have not been studied in detail. Cybrid experiments have shown that heteroplasmy thresholds have to be high for mtDNA mutations (460% for deletions and 490% for A3243G) before respiratory chain activity is impaired. When ATP synthesis has been studied, discrepancies have occasionally been identi®ed between respiratory chain activity and ATP synthesis capacity. This has been reported for the 11778 ND4 and 3460 ND1 complex I gene mutations associated with Leber's hereditary optic neuropathy. The ND4 mutation causes no or only a mild defect in complex I (NADH CoQ reductase) activity but a decrease in oxygen consumption [9±13]. In contrast, the ND1 mutation results in a severe de®ciency of complex I activity, but normal complex I-linked ATP synthesis rates [14] . When rotenone was used to inhibit complex I function to a level identical to that induced by the ND1 mutation, a signi®cant de®ciency of ATP synthesis resulted. The cause of this discrepancy and its relationship to pathogenesis of Leber's hereditary optic neuropathy are not understood.
The relationships between respiratory chain function, ATP synthesis, free radical generation, membrane potential and cell viability have recently been studied in xenomitochondrial cybrids and an osteosarcoma cell line [15 . . ]. The human±ape cybrids exhibited a 40% complex I de®ciency; rotenone was used to induce varying levels of complex I inhibition in the osteosarcoma lines. That study showed that a 25±50% de®ciency in complex I activity caused a 5±20% decrease in cell respiration, a 48±81% increase in reactive oxygen species generation and a 8±27% increase in lipid peroxidation, a 6±13% reduction in mitochondrial membrane potential, a 11±21% decrease in cell growth, and a fourfold to ®vefold increase in cell death. These ®ndings have important implications for the interpretation of the level of complex I de®ciency found in human diseases, particularly the neurodegenerative disorders such as Parkinson's disease in which there is an approximately 35% decrease in complex I activity.
Painful mitochondrial myopathies
Muscle pain and fatigue are very frequent symptoms in patients attending neurology clinics [16] . In most of these patients, clinical examination and standard investigations, including creatine kinase, electromyography and muscle biopsy, are normal. In a small proportion of patients, particularly those with exerciserelated pain, a metabolic myopathy may be diagnosed. The clinical manifestations in these patients and the ®ndings on investigation were placed in context in an accompanying editorial [22] . An appropriate history of myalgia and exercise intolerance with a lactic acidosis and succinate dehydrogenase/COX-positive ragged red ®bres on muscle biopsy, taken together, were strong indicators of an underlying cytochrome b mutation. Although such patients are likely to be rare, identi®cation enables some form of genetic counselling: affected males will not pass on the disease.
Human immunodeficiency virus treatment and mitochondrial dysfunction
Replication of mtDNA is undertaken by DNA polymerase-g, and this enzyme is inhibited by nucleotideanalogue reverse transcriptase inhibitors (NRTIs). The agents include the 2',3'-dideoxy analogues that lack the hydroxyl radical in the 3' position and are incorporated into DNA but prevent elongation of the DNA strand.
Thus, these drugs can induce mtDNA depletion and result in mitochondrial respiratory chain and oxidative phosphorylation de®cits. These effects were ®rst observed in zidovudine-treated patients who developed a myopathy with ragged red ®bres and low mtDNA levels [23, 24] .
Against this background, NRTIs and protease inhibitors have been introduced, often in combination protocols, in the treatment of HIV with dramatic reductions in viral load. However, side effects have been observed, and one of the most important of these, in terms of maintaining drug compliance, is the development of lipodystrophy. This is characterized by wasting of peripheral and facial fat, with fat accumulation in the breasts, dorsocervical and intra-abdominal areas [25, 26] .
These changes may also be associated with insulin resistance and hyperlipidaemia. The cause of lipodystrophy is unknown, but one suggestion is that protease inhibitors interfere with cis-9-retinoic acid metabolism and peroxisome proliferator-activated receptor type g function [27] . However, lipodystrophy, often in association with lactic acidosis, has been noted in patients taking NRTIs who have not been exposed to protease inhibitors. Thus, an alternative explanation has been suggested, linking lipodystrophy to mitochondrial dysfunction [28 . ]. There is some similarity between lipodystrophy and multiple symmetrical lipomatosis type I in terms of distribution of fat deposits. A proportion of patients with multiple symmetrical lipomatosis type I have mitochondrial dysfunction [29] , and some patients with multiple lipomatosis have the A8344G mtDNA mutation [30].
The suggestion that retroviral drugs may be responsible for mitochondrial dysfunction was also explored in the offspring of HIV-infected mothers [31] . Eight children from a cohort of 1754 were thought to have mitochondrial abnormalities. Three were asymptomatic, one had Leigh's syndrome and four had encephalopathy with seizures. Persistent lactic acidosis was seen in the blood of three of the symptomatic children (including the one with Leigh's syndrome) and two of the asymptomatic children, but not in any of the patients' cerebrospinal uid. Only one of the patients had evidence of mitochondrial changes on muscle biopsy. Respiratory chain enzyme activities were only mildly abnormal in two patients (including the one with Leigh's syndrome) and in the liver of one. Levels of mtDNA were normal. There was no clear relationship between maternal or neonatal zidovudine exposure and any of the above abnormalities. Thus, at least in relation to perinatal exposure, there was no convincing evidence of a causal relationship with mitochondrial dysfunction, and certainly nothing to modify current treatment practice in HIV-infected mothers [32 . ].
Models for mitochondrial disease
To date, the cell cybrid system has been the most extensively used model for the study of the biochemical effects of mtDNA mutations. This involves the development of cell lines that are devoid of mtDNA (r 0 ) into which donor mtDNA may be fused from enucleated cells or from platelets. Subsequent culture results in cells (cybrids) that carry the host nuclear DNA and the donor mtDNA. Although cybrid technology has provided valuable insights into mutant mtDNA segregation patterns, the relationship of mutant mtDNA load to biochemical de®ciency, and the in¯uence of different nuclear backgrounds on these processes, there are limitations to its use and application to mitochondrial diseases. The host r 0 cell lines have to be immortal, transformed or neoplastic, and these processes inevitably alter the nuclear background to some degree. Inherent variability requires the study of numerous clonal lines to provide clear patterns of mtDNA-associated biochemical abnormalities.
Several attempts have been made to generate transgenic or knockout animals to model mitochondrial diseases more faithfully. To date, knockouts of the adenine nucleotide transporter [33], mitochondrial superoxide dismutase [34 . ] and mitochondrial transcription factor A [35] have been produced.
The ®rst`mitochondrial' mouse model was recently described [36 . . ]. Enucleated cells were taken from a mouse line carrying a high proportion of mtDNA with a mutation in the 16S ribosomal RNA gene (A2379T). This mutation confers chloramphenicol resistance and increases lactic acid production, suggesting a respiratory chain defect [37] . These cells were fused with a female embryogenic stem cell. The resulting fusion line was grown and cells then microinjected into mouse blastocysts. The resulting mice had no clear mitochondrial phenotype and normal muscle histochemistry. However, the mutant mtDNA was distributed widely in tissues of the resulting transgenic mice, with varying mutant loads of up to 6% of total mtDNA. Biochemical studies were not performed. This model provides the ®rst example of transmitochondrial mice, and the technique holds promise for developing models of primary mtDNA diseases.
Cytochrome oxidase deficiency
Primary COX de®ciency may be caused by mutations in mtDNA or nuclear genes that encode COX subunits, whereas secondary COX de®ciency may be the result of mutations in genes that affect COX assembly or stability, or toxins including free radicals.
Several mutations have now been described in mtDNA COX genes [38±44] and these have variable phenotypes, including cramps with myoglobinuria, pure myopathy, encephalomyopathy and motor neurone disease. A mutation in a nuclear gene that encodes a COX subunit has not yet been reported. However, mutation in the gene that encodes COX10, an assembly protein, has been described in an African family with isolated COX de®ciency [45 . ]. The index patient was born to consanguineous (®rst cousin) parents and developed ataxia at 18 months, encephalomyopathic features including seizures, lactic acidosis and proximal tubulopathy, and died at 24 months. Two siblings died at age 3 years and 5 years, with similar features.
The mutation was recessive and involved a missense mutation in COX10 (heme A:farnesyltransferase), a protein that is responsible for anchoring heme in the oxidase complex [45 . ]. Thus, the COX10 mutation affects COX maturation and assembly. In this respect, the COX10 mutation is similar to the SURF-1 and SCO2 gene mutations, which also affect COX maturation and assembly [46,47,48 . ]. SURF-1 mutations result in Leigh's syndrome, and an absence of surf-1 protein and SURF-1 transcripts [49] with severe de®ciency of COX. The SCO2 gene product is important in the transport of copper to COX, and so de®ciency will impair COX enzymatic function. The clinical presentation of SCO2 patients includes encephalopathy and cardiomyopathy, with an earlier onset and more severe course than that in patients with SURF-1 mutations [50] . The SCO2 mutations also cause severe de®ciency of mtDNA encoded subunits with relative preservation of nuclear encoded subunits IV and Va, whereas nuclear subunits Va and Vb are relatively preserved in SURF-1 mutations [51] .
Friedreich's ataxia
Friedreich's ataxia (FRDA) is caused by the abnormal expansion of an intronic GAA repeat in the gene that encodes frataxin [52] . This results in a de®ciency in frataxin, which is a nonrespiratory chain mitochondrial protein [53, 54] of unknown function.
Knockout of the yeast frataxin homologue (YFH1) results in impaired respiratory function, loss of mtDNA and accumulation of mitochondrial iron. Similar biochemical abnormalities have recently been described in tissue from FRDA patients [55 . ]. In addition, defective oxidative phosphorylation in FRDA patients has been described in vivo using 31 phosphorus magnetic resonance spectroscopy [56 . . ]. The de®ciency of ATP production in that study correlated with the length of the individual patient's GAA repeat, thereby providing a direct correlation between the underlying molecular genetic defect and the mitochondrial abnormality. The pattern of respiratory chain de®ciency in FRDA tissues (reduced complex I±III and aconitase activities) parallels the changes in the mitochondrial superoxide dismutase knockout mouse [34 . ], and suggests that, in FRDA also, the mitochondrial enzyme defects are secondary to oxidative damage. This is further supported by the ®nding of an identical pattern of enzyme de®ciency in liver tissue from patients with Wilson's disease [57] , where copper-mediated oxidative damage is the most likely explanation for the mitochondrial abnormalities.
Frataxin is thought to play some role in mitochondrial iron metabolism. Frataxin de®ciency may lead to increased mitochondrial iron accumulation (as seen in the YFH1 knockout model) at the expense of cytosolic iron, and enhances the production of free radicals. Support for this has come from the recent observation that serum transferrin receptor concentrations are sig-ni®cantly increased in FRDA patients and correlate with GAA repeat length [58 . ]. Homozygous knockout mice are resorbed by embryonic day 8.5 (i.e. embryonic lethality), but show no evidence of iron accumulation [59 . ]. This implies that frataxin is essential for embryological development, and suggests that cell death in the embryos may be due to lack of mitochondrial iron.
Conclusion
The challenges for those working in the ®eld of mitochondrial diseases include a better understanding of the pathogenesis of primary mtDNA disorders and the development of effective treatments. The production of valid animal models of mtDNA mutations will be critically important. The recognition that FRDA and Wilson's disease are due to defects of mitochondrial proteins with secondary free radical-mediated respiratory chain dysfunction offers the opportunity to trial new forms of therapy (e.g. antioxidants) to modify the course of these diseases.
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